Author name: Ying Mak

Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project Read More »

New partnership with the University of Essex to strengthen CANTAB® normative data offering

We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the sensitivity in CANTAB endpoints. Our

New partnership with the University of Essex to strengthen CANTAB® normative data offering Read More »

Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease

Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI).  The landmark initiative will use Cambridge Cognition’s technology to identify the cognitive

Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease Read More »

Supporting research into central nervous system (CNS) disorders to improve patient quality of life

by Martina De LilloClinical ScientistCambridge Cognition Disorders of the Central Nervous System (CNS) affect billions of people worldwide (The Lancet Neurology, 2022), representing an important cause of death and disability around the world. Life expectancy has been extended in the last years which has increased the number of brain pathologies related to aging, such as

Supporting research into central nervous system (CNS) disorders to improve patient quality of life Read More »

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Read More »

2023 CANTAB Research Grant: Exploring the role of intermittent exogenous ketosis on physical and mental fatigue during ultra-endurance performance

We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I got the news about receiving

2023 CANTAB Research Grant: Exploring the role of intermittent exogenous ketosis on physical and mental fatigue during ultra-endurance performance Read More »

Cambridge Cognition strengthens senior management team to deliver growth

Cambridge, UK – 10 April 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing. These strategic additions mark a significant step as the Company continues strengthening its senior leadership team in pursuit of

Cambridge Cognition strengthens senior management team to deliver growth Read More »

2023 CANTAB Research Grant: The microbiota-gut-brain axis in young binge drinkers: The interplay between alcohol use, microbiota composition and neurocognitive functioning

We caught up with the 2023 CANTAB™ Research Grant Secondary Award Winner, Eduardo López-Caneda, from the School of Psychology at the University of Minho​who. He shares with us how the grant will help to understand cognitive training and neuromodulation as a potential strategy to modify alcohol consumption habits. I am deeply grateful to Cambridge Cognition

2023 CANTAB Research Grant: The microbiota-gut-brain axis in young binge drinkers: The interplay between alcohol use, microbiota composition and neurocognitive functioning Read More »

Cambridge Cognition announces scientific advisory board

Cambridge, UK – 21 March 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the formation of a Scientific Advisory Board (SAB). This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers and the collaborative possibilities

Cambridge Cognition announces scientific advisory board Read More »

Digital measures to advance research & quality of life in schizophrenia

Schizophrenia spectrum disorders are complex and serious psychiatric disorders with multifaceted symptoms and associated difficulties, including psychosis, negative symptoms (e.g., loss of motivation), cognitive dysfunction, and functional impairment in major life areas. This multifaceted clinical picture in schizophrenia is also heterogeneous, both across individuals and within individuals over time, posing a challenge for studying groups

Digital measures to advance research & quality of life in schizophrenia Read More »

Scroll to Top